Professor Heather Payne

Professional statement

Professor Heather Payne is a highly regarded clinical oncologist based in London, specialising in the treatment of various urological cancers. With a primary focus on prostate cancer, her areas of expertise also encompass radiotherapy, hormone therapy, image-guided radiotherapy (IGRT), chemotherapy, and brachytherapy. Beyond prostate cancer, Professor Payne is well-versed in managing bladder cancer, kidney cancer, penile cancer, and testicular cancer, showcasing her comprehensive approach to urological oncology.
 
Professor Payne underwent her training at St Mary's Hospital, developing a strong foundation for her subsequent professional endeavours. Currently, she operates within a multidisciplinary team at her bustling practice, where her work extends to pioneering initiatives in the field. Notably, her research contributions encompass hormone therapy, proton beam therapy for prostate cancer, and the innovative use of high-dose-rate brachytherapy in prostate cancer treatment.
 
In addition to her clinical and academic roles, Professor Payne actively engages in research, reflecting her commitment to advancing the field of oncology. Her research interests include sensitisation of hormones and radiotherapy, predictive indices for bowel toxicity with radiotherapy, proton beam therapy for prostate cancer and supporting men in decision-making processes related to prostate cancer. This dedication to research aligns with her holistic approach to patient care.
 
Professor Payne's contributions extend beyond the clinical and research realms. As the chair of the British Uro-oncology Group (BUG) and a trustee of the Prostate Cancer Research Centre, she holds leadership roles within key organisations dedicated to urological oncology. Her reputation for expertise and her compassionate approach make her a trusted figure, particularly in helping patients navigate challenging treatment decisions.